Is Alexandria Real Estate Equities profitable in 2026?

Alexandria posted Q1 2026 net income per share of $2.10, but that included a one-time $366.4M gain on debt extinguishment. Revenue fell 11.5% YoY to $671.02M and Q4 2025 saw a roughly $1.1B net loss from impairments, as of April 27, 2026.

Did Alexandria Real Estate cut its dividend?

Yes. Alexandria cut its quarterly dividend 45%, from $1.32 to $0.72 per share, announced January 26, 2026, alongside a roughly $1.1 billion Q4 2025 net loss driven by non-cash property impairments.

Is Alexandria Real Estate a good stock to buy in 2026?

Analyst consensus rated ARE 'Reduce' as of July 23, 2026, with Zacks at 'Strong Sell' and Morgan Stanley at 'Underweight'. Shares traded near $50, down from a 52-week high of $88.24 and an all-time high of $224.95.

Could AI replace Alexandria Real Estate's lab-leasing business?

Not directly. On the Q1 2026 call, Chairman Joel Marcus called 'push-button drug discovery' overhyped, and EVP Jenna Foger said AI has caused no material change in tenant demand as of April 28, 2026. AI firms like OpenAI have instead eyed Alexandria's vacant lab space for leasing.

Who is Alexandria Real Estate Equities' biggest competitor?

Blackstone is the most capital-heavy rival, closing a $6.3 billion Life Sciences Fund VI (BioMed Realty) in March 2026. BXP and Healthpeak are also pivoting office and healthcare assets into life-science lab space in the same Northeast and coastal clusters.

Is Alexandria Real Estate facing lawsuits in 2026?

Yes. A securities class action filed November 25, 2025 alleges misrepresentation of leasing spreads and occupancy prospects for its Long Island City property. An amended complaint was filed April 15, 2026 and defendants moved to dismiss on May 20, 2026.

Real estate developers · United States

Alexandria Real Estate Equities

are.com ↗

REIT that owns lab and office campuses leased to life science and tech tenants.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from Aug 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call: occupancy and leasing volume update

The call

Alexandria still holds prime lab campuses and long leases, but occupancy, leasing volume, and biotech demand are all sliding at once.

Alexandria Real Estate owns and rents laboratory and office buildings in top biotech neighborhoods like Kendall Square in Boston and Torrey Pines in San Diego. The company is hard to replace because these locations took decades to build up and tenants signed long-term leases, but right now things are breaking down: occupancy dropped from 91.7 percent to 87.7 percent in one year, leasing deals fell in half between quarters, and no major biotech companies signed new leases in early 2026. Rivals like Blackstone and Boston Properties are buying up similar properties and converting old office space into labs, while the bigger threat is that artificial intelligence is making wet labs less necessary for drug discovery, meaning companies may not need to rent as much space going forward. The key thing to watch is whether this is temporary or permanent: if biotech companies start signing leases again in the next few quarters and if the federal government keeps funding research at current levels, Alexandria could stabilize, but if the occupancy keeps dropping and AI really does replace lab work, the company could keep struggling even though it has enough money to survive.

Why

AI pressure: AI-driven computational drug discovery labs, plus AI firms like OpenAI eyeing vacant lab space for compute. AI drug discovery could cut wet-lab demand over time, while AI firms may take empty labs for compute, not biotech leases. Could AI do the core job? Unlikely.

Bigger players: Blackstone (BioMed Realty, $6.3B Life Sciences Fund VI closed Mar 2026), BXP, Healthpeak. Blackstone's new life-science fund and BXP's office-to-lab pivot are actively competing for the same tenants Alexandria needs. Could a giant copy it? Probably.

What protects it. Long, escalating leases with top pharma at flagship campuses like Kendall Square and Torrey Pines still anchor most of its cash flow.

What would change this call

Occupancy and public-biotech leasing figures in Alexandria's Q2 2026 earnings on Aug 4, 2026. Shows whether tenant losses to rivals are stabilizing or worsening.
Renewal outcome on the 232K sq ft Waltham lease and other 2027 expirations (3.4M sq ft). Indicates whether tenants are leaving for competitor space or exiting the market.
Ruling on the securities class-action motion to dismiss, expected within six months of Jul 2026. Shows whether legal exposure adds further pressure on the company.

Key numbers

Occupancy fell 91.7% to 87.7% year over year (2026-04-28)
Zero public-biotech leases signed in Q1 2026 (2026-04-28)
Dividend cut 45%, from $1.32 to $0.72 per share (2026-01-26)

Named risks

Occupancy decline (91.7% to 87.7% YoY) with zero public-biotech leases in Q1 2026. Severity: high
Securities class action over Long Island City leasing disclosures, motion to dismiss pending as of May 2026. Severity: medium
FY2027 NIH budget proposal of ~12% cut could reduce biotech tenant demand. Severity: medium
3.4M sq ft (10.5% of ARR) of leases expire in 2027 including a non-renewing Waltham tenant. Severity: medium
45% dividend cut and $1.1B impairment loss signal balance-sheet stress despite deleveraging. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Blackstone (BioMed Realty)	gaining on	Closed $6.3B Life Sciences Fund VI in Mar 2026 targeting same tenant pool
BXP (Boston Properties)	contesting	Expanding office-to-lab pivot (>6M sq ft) in Alexandria's Northeast strongholds
Healthpeak Properties	contesting	Life science occupancy improved to 77.7% in Q1 2026 while pivoting capital into R&D assets
OpenAI (indirect, AI/tech firms)	gaining on	Reported considering leasing Alexandria's vacant 455 Mission Bay lab space in 2025

Questions people ask

Is Alexandria Real Estate Equities profitable in 2026?: Alexandria posted Q1 2026 net income per share of $2.10, but that included a one-time $366.4M gain on debt extinguishment. Revenue fell 11.5% YoY to $671.02M and Q4 2025 saw a roughly $1.1B net loss from impairments, as of April 27, 2026.
Did Alexandria Real Estate cut its dividend?: Yes. Alexandria cut its quarterly dividend 45%, from $1.32 to $0.72 per share, announced January 26, 2026, alongside a roughly $1.1 billion Q4 2025 net loss driven by non-cash property impairments.
Is Alexandria Real Estate a good stock to buy in 2026?: Analyst consensus rated ARE 'Reduce' as of July 23, 2026, with Zacks at 'Strong Sell' and Morgan Stanley at 'Underweight'. Shares traded near $50, down from a 52-week high of $88.24 and an all-time high of $224.95.
Could AI replace Alexandria Real Estate's lab-leasing business?: Not directly. On the Q1 2026 call, Chairman Joel Marcus called 'push-button drug discovery' overhyped, and EVP Jenna Foger said AI has caused no material change in tenant demand as of April 28, 2026. AI firms like OpenAI have instead eyed Alexandria's vacant lab space for leasing.
Who is Alexandria Real Estate Equities' biggest competitor?: Blackstone is the most capital-heavy rival, closing a $6.3 billion Life Sciences Fund VI (BioMed Realty) in March 2026. BXP and Healthpeak are also pivoting office and healthcare assets into life-science lab space in the same Northeast and coastal clusters.
Is Alexandria Real Estate facing lawsuits in 2026?: Yes. A securities class action filed November 25, 2025 alleges misrepresentation of leasing spreads and occupancy prospects for its Long Island City property. An amended complaint was filed April 15, 2026 and defendants moved to dismiss on May 20, 2026.

Timeline

2026-07-22Market cap reported near $8.6-8.8B, down from $20.44B on Mar 31, 2026; shares near $50
2026-07-20Alexandria delivers 427,000 sq ft R&D hub to Bristol Myers Squibb at Campus Point
2026-05-20Defendants file motion to dismiss securities class action
2026-04-27Q1 2026 results: revenue $671.02M (-11.5% YoY), FFO/share $1.73 miss
2026-04-15Amended securities class-action complaint filed
2026-04-01White House FY2027 budget proposes ~12% NIH funding cut
2026-03-01Blackstone closes $6.3B Life Sciences Fund VI
2026-02-01Alexandria repurchases $1.33B senior notes, issues $750M new notes at 5.25%
2026-01-26Dividend cut 45% to $0.72/share; Q4 2025 net loss ~$1.1B disclosed
2025-11-25Securities class action filed over Long Island City leasing claims

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Primoris Services Poly Developments and Holdings Group China Merchants Shekou Industrial Zone Holdings